SCHEMBL25370796

SCHEMBL25370796

Cc1nc(C(F)(F)F)ccc1S(=O)(=O)N1CC2(CN(C[C@@H]3COCCO3)C2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 2/20 0.40
▸ USP2 O75604 1/20 0.36
▸ MAPT P10636 1/20 0.31
▸ BRS3 P32247 8/20 0.31
▸ NR1I2 O75469 2/20 0.31
▸ PSEN1 P49768 2/20 0.30
▸ PSEN2 P49810 2/20 0.30
▸ APH1B Q8WW43 2/20 0.30
▸ NCSTN Q92542 2/20 0.30
▸ APH1A Q96BI3 2/20 0.30
▸ PSENEN Q9NZ42 2/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ KDM4E B2RXH2 2/20 0.30
▸ HPGD P15428 1/20 0.30
▸ ALOX12 P18054 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ TLR7 Q9NYK1 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30567029 1.00 TRPV4 (0.40) TRPV4USP2MAPTBRS3NR1I2
SCHEMBL25370802 1.00 TRPV4 (0.40) TRPV4USP2MAPTBRS3NR1I2
SCHEMBL25372864 0.88 TRPV4 (0.42) TRPV4MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL25372869 0.88 TRPV4 (0.42) TRPV4MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL26066191 0.88 USP2 (0.41) TRPV4USP2MAPTSMN1; SMN2KDM4E
SCHEMBL25370942 0.86 TRPV4 (0.43) TRPV4BRS3NR1I2KDM4E
SCHEMBL25371995 0.86 TRPV4 (0.40) TRPV4MAPTPSEN1PSEN2APH1B
SCHEMBL25368952 0.86 TRPV4 (0.40) TRPV4MAPTPSEN1PSEN2APH1B
SCHEMBL25368955 0.86 TRPV4 (0.40) TRPV4MAPTPSEN1PSEN2APH1B
SCHEMBL25369649 0.84 TLR7 (0.42) TRPV4MAPTPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 — — US claimed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 — — WO claimed
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 — — US disclosed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP TRPV4 4535/4885USP2 3199/4885MAPT 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback